Interstitial Lung Disease Multidisciplinary Meeting Diagnostic Labels & Resources

1. Common Diagnostic Labels

We suggest that during the presentation of clinical, radiological and pathological findings, the key positive and negative findings are presented, using terms suggested by international expert bodies where possible. We suggest that specific diagnoses are applied only upon consensus discussion.

| Common Diagnoses | Acronym |
|---|---------|
| Idiopathic pulmonary fibrosis | IPF |
| Non-specific interstitial pneumonitis | NSIP |
| Cryptogenic organising pneumonia | COP |
| Desquamative interstitial pneumonia | DIP |
| Respiratory bronchiolitis-interstitial lung disease | RB-ILD |
| Pleuro-parenchymal fibroelastosis | PPFE |
| Lymphoid interstitial pneumonia | LIP |
| Acute interstitial pneumonia | AIP |
| Unclassifiable interstitial pneumonia, [state if provisional] | |
| Connective tissue disease related interstitial lung disease, [include histological subtype & connective tissue disease] | CTD-ILD |
| Hypersensitivity pneumonitis [acute, chronic] | [A/C]HP |
| Eosinophilic pneumonia [acute, chronic] | [A/C]EP |
| Langerhans cell histiocytosis | LCH |
| Pulmonary lymphangioleiomyomatosis | PLAM |
| Sarcoidosis, [specify organ involvement] | |
| Dust induced disease, [specify dust] | |
| Drug induced lung disease, [specify drug] | |
| Pulmonary vasculitis, [specify subtype] | |
| Pulmonary alveolar proteinosis | |
| Primary pulmonary haemosiderosis | |
| Primary alveolar microlithiasis | |

ILD MDM Toolkit Guide Page 1 of 3

2. Research Labels

We suggest the principal diagnosis avoids the use of terms that are currently the subject of further research and validation. Instead, those conditions should be recorded as secondary diagnoses.

| Research Terminology | Acronym |
|---|---------|
| Interstitial pneumonia with autoimmune features | IPAF |
| Combined pulmonary fibrosis and emphysema | CPFE |
| Familial interstitial lung disease | |
| Smoking related interstitial lung disease | |

3. Useful References for the Diagnosis of Common MDM Presentations

| No. | Reference | Topic | Manuscript Type |
|-----|---|--|------------------------|
| 1 | Prasad, J.D., et al. Respirology, 2017. 22(7): p. 1459-1472 | MDM Governance | Position Paper |
| 2 | Jo, H.E., et al. Respirology, 2017. 22(7): p. 1436-1458 | IPF | Position Paper |
| 3 | Raghu G et al. Am J Respir Crit Care Med. Vol 183. pp 788–824, 2011 | IPF | Consensus Statement |
| 4 | Lynch DA et al. Lancet Respir Med. 2018 Feb;6(2):138-153 | IPF | Expert opinion |
| 5 | Travers, W et al. Am J Respir Crit Care Med. Vol 188, Iss. 6, pp 733–748, Sep 15, 2013 | IIP | Consensus Statement |
| 6 | Vasakova M et al. Am J Respir Crit Care Med. Vol 196, Iss 6, pp 680–689, Sep 15, 2017 | HP | Expert Opinion |
| 7 | Salisbury ML et al. Am J Respir Crit Care Med. 2017 Sep 15;196(6):690-699 | НР | Expert Opinion |
| 8 | Fischer A et al. Eur Respir J 2015; 46: 976– 987 | IPAF | Consensus Statement |
| 9 | Ryerson CJ et al. Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254 | Unclassifiable ILD and Diagnostic Confidence Criteria | Consensus Statement |
| 10 | Skolnik K and Ryerson CJ. Respirology. 2016 Jan;21(1):51-6 | Unclassifiable ILD | Expert Opinion |
| 11 | Baughman R et al. Am J Respir Crit Care Med. Vol 183. pp 573–581, 2011 | Sarcoidosis | Expert Opinion |

ILD MDM Toolkit Guide Page 2 of 3

ILD MDM Diagnostic Labels & Resources

| 12 | Raoof S et al. Chest 2016; 150(4):945-965 | Cystic Lung Disease | Expert Opinion |
|----|--|-------------------------|------------------------|
| 13 | Van den Hoogen F et al. Arthritis Rheum. 2013; 65: 2737-47 | Scleroderma | Consensus statement |
| 14 | Aletaha D, Arthritis Rheum. 2010; 62: 2569-81 | Rheumatoid Arthritis | Consensus statement |
| 15 | Lundberg IE et al. Arthritis Rheum. 2017; 69: 2271–2282 | Myositis | Consensus statement |
| 16 | Bloch D, Arthritis Rheum. 1990; 33: 1068-73 | Pulmonary Vasculitis | Consensus statement |
| 17 | Henderson DW et al. Int J Occup Environ Health. 2004 Jan-Mar;10(1):40-6 | Asbestosis | Expert Opinion |

4. Other Resources

- Pulmonary Fibrosis Australasian Clinical Trials Network (PACT) http://www.crepf.org.au/pact
 - o Provides a list of current clinical trials in Australasia
- Australian IPF Registry: https://lungfoundation.com.au/healthprofessionals/idiopathic-pulmonary-fibrosis-registry/
 - Provides information for clinicians and participants in the Australian IPF registry
- Drug Induced Lung Diseases Pneumotox: http://www.pneumotox.com/
 - o Provides information about known drug induced pulmonary toxicities

ILD MDM Toolkit Guide Page 3 of 3